Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Acasti Pharma (Nasdaq: ACST) has achieved a significant milestone in its pivotal Phase 3 STRIVE-ON safety trial for GTX-104, a novel injectable formulation of nimodipine targeting aneurysmal subarachnoid hemorrhage (aSAH). The company announced that over 50% of the 100-patient enrollment target has been reached. The trial, comparing IV GTX-104 with oral nimodipine, focuses on safety, particularly adverse events like hypotension. Enrollment began in October 2023, and the company expects to complete it by late 2024 to early 2025, with a potential NDA submission in the first half of 2025. CEO Prashant Kohli attributes this progress to the dedication of clinical trial sites and the Acasti team. Dr. Abhishek Ray from Case Western Reserve University highlighted the challenges of oral nimodipine in aSAH patients and the promise of GTX-104 as an IV alternative.
- Achieved over 50% enrollment in pivotal Phase 3 STRIVE-ON trial for GTX-104.
- Enrollment completion anticipated by late 2024 to early 2025.
- Potential NDA submission on track for the first half of 2025.
- The trial's primary endpoint is safety, measured by adverse events such as hypotension, which carries inherent risks.
Insights
The STRIVE-ON trial reaching the 50% enrollment milestone marks a significant step in the development of GTX-104, Acasti Pharma's novel injectable formulation. This drug aims to address the high unmet medical needs associated with aneurysmal subarachnoid hemorrhage (aSAH), a condition characterized by bleeding in the space around the brain. Traditional oral nimodipine is often challenging to administer consistently due to the patient's severe neurological complications, such as dysphasia or the need for mechanical ventilation.
The fact that GTX-104 is an intravenous formulation could make a substantial difference in patient care. By potentially providing more reliable drug delivery, it could improve outcomes for patients suffering from this severe condition. Achieving half of the patient enrollment also suggests that interest and optimism within the clinical community are high, which is encouraging for the trial's future success.
From a financial perspective, the progress in the STRIVE-ON trial is noteworthy. Successful completion of this Phase 3 trial, followed by an NDA submission in H1 2025, could pave the way for FDA approval, potentially leading to significant revenue generation for Acasti Pharma. The company's focus on a rare disease with high unmet medical needs could also make GTX-104 eligible for orphan drug status, potentially providing market exclusivity and other benefits.
However, investors should also consider the timeline. The estimated completion of patient enrollment by late 2024 or early 2025 means that any potential financial windfall is some time away. Additionally, the primary endpoint being safety-related rather than efficacy-focused underscores that this trial is important but not the final determinant of the drug's market potential.
The market for treatments addressing aSAH is currently limited and the introduction of an effective intravenous alternative to oral nimodipine could potentially reshape treatment protocols. The current standard of care presents significant administration challenges, which GTX-104 aims to overcome. If GTX-104 can demonstrate superior safety and comparable or better efficacy, it could capture a significant share of this niche market.
Given the specialty nature of this market, GTX-104 could command premium pricing, which would benefit Acasti's financial performance. Additionally, the successful progression of this Phase 3 trial could enhance Acasti's reputation within the biopharma sector, potentially opening doors for future partnerships or acquisitions.
Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025
PRINCETON, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that the Company’s pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has exceeded the
“Since dosing the first patient in STRIVE-ON last October, we have continued to build momentum by activating high volume neurocritical care hospitals across the country with unrelenting focus on executing patient enrollment and investigator engagement,” said Prashant Kohli, CEO of Acasti. “Achievement of our
“Patients with aSAH require intensive management and present with a variety of complications that make consistent administration of oral nimodipine difficult especially in patients with severe neurological deficits with dysphasia or requiring mechanical ventilation,” said Dr. Abhishek Ray, Associate Professor of Neurological Surgery at University Hospitals Cleveland, Case Western Reserve University School of Medicine. “GTX-104 shows great promise as an IV alternative to the current standard of care, and we look forward to assessing the data obtained from this trial.”
About aneurysmal Subarachnoid Hemorrhage (aSAH)
aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm. Approximately
About the GTX-104
GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTX-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion.
GTX-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTX-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTX-104 has the potential to better manage hypotension in aSAH patients. GTX-104 has been administered in over 150 healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine. The addressable market in the United States for GTX-104 is estimated to be about
About Acasti
Acasti is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Acasti's lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical asset, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.
For more information, please visit: www.acasti.com.
Forward-Looking Statements
Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Such forward looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms "believes," "belief," "expects," "intends," "anticipates," "estimates", "potential," "should," "may," "will," "plans," "continue", "targeted" or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including statements regarding the Company's anticipated enrollment and NDA submission schedule for the STRIVE-ON trial, GTX-104’s commercial prospects, and GTX-104's potential to bring enhanced treatment options to patients suffering from aSAH are based upon Acasti's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions of the Phase 3 safety trial for GTX-104; (ii) regulatory requirements or developments and the outcome and timing of the proposed NDA application for GTX-104; (iii) changes to clinical trial designs and regulatory pathways; (iv) legislative, regulatory, political and economic developments; and (v) actual costs associated with Acasti's clinical trials as compared to management's current expectations. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and are filed by Acasti from time to time with the Securities and Exchange Commission and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws.
For more information, please contact:
Acasti Contact:
Prashant Kohli
Chief Executive Officer
Tel: 450-686-4555
Email: info@acastipharma.com
www.acasti.com
Investor Relations:
LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: mmoyer@lifesciadvisors.com
FAQ
What milestone did Acasti Pharma achieve in the GTX-104 Phase 3 STRIVE-ON trial?
When is Acasti Pharma expected to complete patient enrollment in the STRIVE-ON trial?
What is the primary endpoint of the GTX-104 Phase 3 STRIVE-ON trial?
When could Acasti Pharma potentially submit the NDA for GTX-104?
What makes GTX-104 potentially better than oral nimodipine for aSAH patients?
